Some good news came out of Gilead (GILD 0.56%) this morning, as the company's drug Sofosbuvir was deemed safe enough to continue with a critical phase 3 trial. This drug is a vital part of Gilead's focus on hepatitis C, but this class of drugs has had some safety questions in the past. In the following video, Fool health-care analyst David Williamson tells investors what the key things to watch will be, now that Gilead has gotten the go-ahead to move into this major phase 3 trial.
So Far, So Good for Gilead's Blockbuster
By Dave Williamson – Mar 26, 2013 at 7:43PM
NASDAQ: GILD
Gilead Sciences
Market Cap
$147B
Today's Change
(-0.56%) $0.67
Current Price
$118.17
Price as of November 10, 2025 at 3:58 PM ET
Sofosbuvir is safe enough to continue its phase 3 trial.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid